{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-032946","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2026-08-14T11:55:46+00:00","discovered_at":"2026-08-14T12:00:08.256908+00:00","generated_at":"2026-08-14T12:00:15.940432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Galectin reports Q2 net loss $9.2M; FDA agrees on Phase 3 design for belapectin","bullets":["Net loss $9.2M ($0.14/share) vs $7.6M ($0.12/share) in Q2 2025; R&D $2.1M, G&A $1.8M.","FDA alignment on Phase 3 trial design for belapectin in MASH cirrhosis; protocol submission expected 3Q 2026.","Chairman Richard Uihlein converted $105.8M debt (principal $91M + interest $14.8M) into 34.4M shares, effective July 31, 2026.","Cash $13.2M at June 30, 2026; $10M line of credit available; cash runway through June 2027.","NAVIGATE trial data published in Hepatology and Gastro Hep Advances; EASL presentations."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-032946","json":"https://secwatch.observer/filing/0001140361-26-032946.json","markdown":"https://secwatch.observer/filing/0001140361-26-032946.md","text":"https://secwatch.observer/filing/0001140361-26-032946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126032946/0001140361-26-032946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036126032946/ef20080011_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T12:00:15.940432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}